Drug Profile
MTL CEBPA
Alternative Names: MTL-CEBPALatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator MiNA Therapeutics; University of California at San Francisco; University of Texas Southwestern Medical Center
- Developer MiNA Therapeutics; National University Hospital (Singapore)
- Class Antineoplastics; Oligonucleotides; RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Liver cancer
- Phase I/II Mucopolysaccharidosis I
- Preclinical Acute myeloid leukaemia
- No development reported Colorectal cancer; Liver disorders; Solid tumours
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in United Kingdom (IV)
- 25 Oct 2023 MTL CEBPA is available for licensing as of 25 Oct 2023. 9401862
- 25 Oct 2023 Preclinical trials in Acute myeloid leukaemia in United Kingdom prior to October 2023 (Parenteral)